Higher Serum Endocan Level Is Associated with Alzheimer Disease
| Autor: | Cemile Ozsurekci, Filiz Akbiyik, Burcu Balam Yavuz, Fatih Sumer, Aykut Sagir, Gurkan Guner, Meltem Halil, Gozde Sengul Aycicek, Cafer Balci, Hatice Caliskan, Rana Tuna Dogrul, Muhammet Cemal Kizilarslanoglu, Mustafa Cankurtaran, Hacer Dogan Varan |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Endothelium Cognitive Neuroscience Neuropsychological Tests Gastroenterology Proinflammatory cytokine Pathogenesis 03 medical and health sciences 0302 clinical medicine Alzheimer Disease Reference Values Internal medicine medicine Humans Cognitive Dysfunction Geriatric Assessment Aged Aged 80 and over Receiver operating characteristic business.industry Area under the curve Montreal Cognitive Assessment medicine.disease Pathophysiology Neoplasm Proteins Psychiatry and Mental health medicine.anatomical_structure ROC Curve 030220 oncology & carcinogenesis Female Proteoglycans Geriatrics and Gerontology Alzheimer's disease business Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | Dementia and Geriatric Cognitive Disorders. 44:303-310 |
| ISSN: | 1421-9824 1420-8008 |
| DOI: | 10.1159/000485245 |
| Popis: | Background: The novel molecule endocan, which is released by endothelium and is regulated by proangiogenic and proinflammatory cytokines, may have a role in the pathophysiology of Alzheimer disease (AD). The aim of this study was to evaluate the relationship between serum endocan levels and AD. Methods: A total of 134 patients (47 AD, 42 amnestic mild cognitive impairment [aMCI], and 45 control patients) 65 years of age and older were recruited in this study. Cognitive status of the patients was evaluated by performing the Montreal Cognitive Assessment (MOCA) and the Mini-Mental State Examination (MMSE). Serum endocan levels were measured with an enzyme-linked immunosorbent assay kit. Results: Median serum endocan level was significantly higher in AD patients (380.1 ng/mL) than in both aMCI patients (247.7 ng/mL) and controls (277.6 ng/mL; p < 0.01). Serum endocan level had a weak but significant correlation with MMSE and MOCA scores (r = –0.219 and r = –0.232; p = 0.012 and p = 0.01, respectively). Serum endocan level was detected as a factor independently associated with AD. The cutoff serum level of endocan predicting AD was >288.94 ng/mL in receiver operating characteristic curve analysis (area under the curve 0.71, 95% CI 66.7–90.9, sensitivity 80.9%, specificity 59.8%; p < 0.01). Conclusion: Higher serum endocan levels may be associated with the pathogenesis of AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|